SC
VIVO

Sarissa Consulting’s Meridian Bioscience Inc VIVO Stock Holding History

Sarissa Consulting’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$576K Buy
+18,267
New +$591K 0.59% 42

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sarissa Consulting's VIVO Position: Q3 2022 in Review

Sarissa Consulting opened a new position in Meridian Bioscience Inc (VIVO) in Q3 2022: 18,267 shares worth $576K. The stake represents 0.59% of the portfolio and ranks #42 among its holdings.

203 funds tracked by Wall St. Rank hold VIVO as of Q3 2022.

  • Sarissa Consulting held 18,267 shares of Meridian Bioscience Inc worth $576K as of Q3 2022.
  • Meridian Bioscience Inc was a new Sarissa Consulting position in Q3 2022.
  • Meridian Bioscience Inc made up 0.59% of Sarissa Consulting's portfolio in Q3 2022, its #42 holding.
  • 203 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2022.

Based on Sarissa Consulting's 13F filing for Q3 2022, filed 14 Nov 2022.